|
| |
Visiongain
Reports
http://www.bioportfolio.com/cgi-bin/acatalog/Visiongain_2005.html
 |
Alzheimers disease (AD) is the third leading cause of death in recent
times and with an unprecedented patient potential, this disease area
attracts awareness from a broad base of stake holders. With the grey
population being the single most influencial factor in driving the economic
growth within this sector, Visiongain believes the real market of the AD
industry still remains untapped. |
|
|
The World Health Organization (WHO) estimates that over 2.5 million
people globally suffer from Multiple Sclerosis (MS). With the present global
population growing to an unprecedented height of 6.5 billion in 2005 and
growth rate anticipated to reach 7.6 billion by 2020, the prevalence and
onset of MS in children and particularly adults is expected to rise
exponentially. |
|
|
The market for hypertensives - led by the angiotensin II antagonists -
is one of the largest and most profitable in the global pharmaceutical
market, with total anti-hypertensive sales of $36600m in 2006. Hypertension,
or high blood pressure, is a worldwide epidemic: by 2025 visiongain predict
that worldwide there will be more than 1.5 billion sufferers of this
disease. Modern lifestyles, such as poor diet and lack of exercise, are the
main contributory factors to elevated blood pressure. Consequently, the
incidence and prevalence of hypertension are increasing rapidly in both
developed and developing countries. |
|
|
Diabetes affects approximately 246 million people worldwide and this
number is increasing. The IDF predict 380 million diabetics by 2025. The
Global Diabetes drug treatment market was valued at over $21 billion in 2006
and the market is still expanding rapidly due to the high prevalence of
diabetes and lifestyle changes. You cannot afford to ignore this market. To
ignore this report when your competitors are reading it, would be a mistake.
I urge you to read this report today. |
|
|
- Do you know what the next major blockbuster will be?
- In the year 2000, when visiongain first produced their Blockbuster Drug
market report there were 55 blockbuster drugs – now there are over 100.
|
|
|
Visiongain believe that the market for non-opioid drugs is the fastest
growing segments in pain management with a CAGR of 8.12% for the period
2006-2012. The brand new report entitled “The Global Non-Opioid Market in
Pain Management” has highlighted a number of innovative pipeline
developments that are set to shape the industry over the medium term. |
 |
Amyotrophic lateral sclerosis (ALS) also known as Lou Gehrig's disease
in the US, Maladie de Charcot in France and Motor Neuron Disease (MND) in
the UK is a progressive neuromuscular disease characterised by the
progressive degeneration of motor nerve cell in the brain (upper motor
neurons) and spinal cord (lower motor). To date there is no cure for ALS.
Present day medical management of the disease through the combinatorial use
of medications and advancements in state-of-art technological devices for
nutrition and breathing, have markedly increased the survival rate of ALS
sufferers. |
 |
Increasingly the large pharmaceutical companies are pumping money and
ambition into the DNA/RNA therapy market. Whether its through forming
collaboration/licensing agreements, or acquiring smaller companies they can
see the financial opportunities. In particular the large pharmaceutical
companies Pfizer, sanofi-aventis, Eli Lilly & Company and Merck & Co all
have substantial investment in the RNA/DNA therapy products market. With
Merck & Co in particularly showing its faith in the future potential of this
market by taking the gamble of acquiring the specialist RNAi company Sirna,
towards the end of 2006. |
 |
"By 2010, almost 50 percent of children in North America and 38 percent
of those in the European Union will be overweight, researcher has found".
For pharmaceutical companies looking to target growing successful markets,
the anti-obesity drug treatment market offers unique opportunities. |
 |
Cigarette smoking is the most important source of preventable and
premature morbidity worldwide. Currently, the number of smokers across the
globe is estimated at 1.3 billion. Political moves are leading to national
bans of smoking in public places, with the long-term aim to reduce the cost
to the health sector. But what will be the short-term spending on smoking
cessation therapies? |
 |
Marinol®, Cesamet®, Sativex ® and Rimonabant are all
commercially-marketed cannabinoids. They treat a variety of conditions from
weight-loss to pain relief. The introduction of cannabinoids into the
pharmaceutical marketplace has begun, and attitudes to the drugs are
changing. This increased acceptance will lead to greater market penetration,
and the importance of the area will be seen with the first cannabinoid
reaching blockbuster status before the end of the decade. |
 |
With the recent Alzheimer's Association International Conference
suggesting a new era of hope for sufferers of the illness, drug trials have
shown some enlightening discoveries. |
|
|
Gastrointestinal (GI) disorders are set to affect over 250 million
people in the seven largest pharma markets, by 2012. As generations of
people become more obese and consume increasingly poor diets then so too
will the number of people suffering from these disorders rise. |
 |
"Teva has a robust corporate strategy that should serve it well for
years to come, driving strong growth and further innovation. Teva is
therefore one of the most exciting and dynamic companies in the global
pharmaceutical industry," finds visiongain report.
Just some of the recent headlines surrounding Teva:
- Court rules against Teva in patent dispute – May 11th
- Teva gets tentative ok for generic of Eli Lilly’s Gemzar – May 8th
- Teva Announces Approval and Shipment of Generic Omnicef – May 14th
- Teva loses Merck generics race to U.S. rival Mylan - May 14th |
 |
Driven by demographic trends, such as an increasing aged population, the
global ophthalmic pharmaceutical market is set to become a serious growth
area experiencing a compound annual growth rate of 11.11 per cent to 2012.
This report explains just how this market will experience growth over the
medium term future. Also do you know what the drivers and restraints of the
market are? This report not only reveals these, but also details what
strategies can be used to maximize profits from the drivers and restraints. |
 |
Founded by Indian Scientist Dr Anji Reddy in 1984, the company has
developed into a fast-growing international corporation, with headquarters
in Hyderabad, Andhra Pradesh, India. During the fiscal year 2006, Dr.
Reddy’s was the third-largest Indian pharmaceutical company, with net
revenue of $546m. However they have not rested there. Throughout 2007, Dr.
Reddy’s has been jostling for leadership among the Indian companies, due to
spectacular growth in recent quarters. This company is moving rapidly. Are
they a major competitor of yours? Are you partnering with them? Whatever
your relationship with the company you need to be fully aware of how they
operate and will develop over the next 5 years. |
 |
The number of blockbusters continues to increase. The number is set to
increase to 112 in 2007. Of the products set to receive FDA approval this
year and generate blockbuster status on an annual basis, GSK's Cervarix,
intended for the prevention of infection and lesions from the two
cancer-causing types of HPVs holds great potential. |
 |
With 4 drugs now in the marketplace (a 100% rise from 2 years ago), the
cannabinoid market continues to grow. Attitudes to the drugs are changing
ensuring greater market penetration, and the first cannabinoid blockbuster
is now a certainty. |
 |
AMD is the most common cause of vision loss in the developed world for
those over 50 years of age. We estimate there are over 20 million cases in
the US and Europe. Dry AMD accounts for 90% of cases and has no suitable
cure. Wet AMD drug sales will soon see the first blockbuster. Novartis
achieved first to market success with their Visudyne drug in 1999. However
work from Pfizer selling Macugen and Lucentis from Genentech have seen it
sales reduced. These drugs are refered to in the press as ‘miracle drugs’ –
saving sight for millions. But issues over prescribing still remain. |
 |
In a market believed to approach 5 million people in the leading pharma
markets, the market for rheumatic anti-inflammatory drugs is both profitable
and set to increase due to new launches. The annual revenue to Q3 2006, from
the main prescription anti-inflammatory drugs worldwide, including non
steroidal anti-inflammatories (NSAIDs), anti-rheumatic corticosteroid
combinations and specific anti-rheumatics was in the order of $16bn
worldwide. This market cannot be ignored. A life-long disease with no cure,
the disease has been targeted greatly by pharma companies with the launch of
novel targetted biologic therapies. However this has meant that the market
for severe RA has become crowded - but is it saturated? |
 |
Over 160+ pages dedicated to tissue engineering and stem cell analysis.
The market potential of this technology is so huge that revenues may be in
excess of $10 billion by 2013. This is a market that you should be part of -
NOW!! With a complex regulatory structure still to overcome, yet continued
high level investment, many of your competitors are aware of the the
commercial opportunities within Tissue Engineering & Stem Cell Technology. |
 |
With headquarters in Basel, Switzerland, Novartis is recognised as being one
of the strongest performing pharmaceutical companies in terms of sales, high
revenue growth, acquisitions, breadth of portfolio, product launches and
pipeline developments. In 2006 - ten years after its inception - Novartis
generated total net sales of $37bn worldwide. |
 |
The two major problems for biotech drugs are their mode of delivery and
relative instability. The majority of delivery methods for biological drugs
involve injection, which is not necessarily ideal for most indications. As
the biotech sector starts to heat up, the industry has started to look for
new ways of delivering these highly successful drugs. |
 |
'The Autoimmune Inflammatory Bowel Disease Market Outlook to 2012' is a
new report from visiongain providing analysis of the current and future
market for IBD drugs across all major indications. Forecasts are given based
on new product launches, upcoming patent expiry dates, and ongoing clinical
trials to enable you to predict changes in the dynamics of the global IBD
market. Autoimmune disease is a multimillion dollar market set to increase
as world prevalence rates rise and the population lives longer. Inflammatory
bowel disease (IBD) affect millions of people worldwide with 2.8 million
currently diagnosed with ulcerative colitis (UC) or Crohn’s disease (CD) in
the US alone. The incidence of IBD is rising in developing countries around
the world. Currently the global market is estimated at $16bn and this is set
to continue to rise. |
 |
Key questions remain over theranostics. How can your company secure key
successes and ideals in personalized medicine - aiming the right drug at the
right person and at the right time. Plus with increased FDA regulation, how
can we guarantee that that specific drug is safe for that individual. These
issues are not going away, but one report can make it alot easier for you
and your company. |
 |
Stem cells are without doubt the most controversial area of science at
the moment. The world markets have latched onto the potential offered by
stem cells to modern medicine and, as a result, the research is in the
public eye on an almost daily basis. Are you fully informed of the market
potential of stem cell work? Do you know which companies and research
organisations you must work with now? This report tells you.
So what is all the controversy about? And what products are we likely to
see, in what areas and when, if stem cell work continues at pace? |
 |
"Lung cancer vaccine to be tested" "New US bill requires cancer vaccine
for girls" "Cancer vaccine too expensive".
These are just some of the news headlines that have seen the world cancer
vaccine market turned on its head. The benefits are unquestionable, the
costs of the drugs however may yet see take-up slow. How will this effect
your company? This report will tell you.
There are two types of cancer vaccines:
> Prophylactic cancer vaccines, designed to prevent the development of
cancer, they are given to healthy subjects to prevent infection with
cancer-causing viruses
> Therapeutic cancer vaccines, designed to treat existing cancers, they are
given to cancer patients to stimulate the immune system into recognising and
destroying their existing cancer |
 |
The purpose of visiongain’s Developing Markets Series is to examine
prospects for the growth of pharmaceutical revenues in the developing
economies of Asia, Latin America and Eastern/Central Europe in three linked
reports. Central and Eastern European (CEE) Developing Markets for
Pharmaceuticals, 2006-2011 – Part 3 of Developing Markets - discusses
prospects for the large developing market of Central and Eastern Europe. The
other reports discuss Asia and Latin America respectively. Importantly, the
growth of pharmaceutical markets in economically developing nations has the
potential to offset serious problems currently being experienced by the
global industry. The purpose of this visiongain report is to examine the
prospects for the growth of pharmaceutical revenues in the developing
economies of Central and Eastern Europe, at both regional and national
level. |
 |
The monoclonal market is set to expand dramatically. Ten years ago there
were only two monoclonal antibody drugs on the world market, now there are
nineteen FDA approved therapies – including six blockbuster drugs. The
market in 2005 was worth over $13bn, worldwide, representing an astounding
growth of 37% - can you believe it? Well you should and to make sure you
capture an increased share of this growth order this report NOW. Biotech
pipelines are overflowing with over 160 monoclonal antibody based drugs; the
market is thriving!
Will the current monoclonal blockbusters continue to grow? What are the
hottest projects in the pipeline? What will restrain the market in the
future? These are questions you need to know the answers to. |
 |
The purpose of visiongain’s Developing Markets Series is to examine the
prospects for the growth of pharmaceutical revenues in the developing
economies of Asia, Latin America and Eastern/Central Europe. Latin American
Developing Markets for Pharmaceuticals, 2006-2011 discusses prospects for
the large developing market of Latin America. Importantly, the growth of
pharmaceutical markets in Latin America has the potential to offset serious
problems currently being experienced by your industry. The purpose of this
visiongain report is to examine the prospects for the growth of
pharmaceutical revenues in the developing economies of Latin America, at
both regional and national level. |
 |
Will the economic growth in new Asian markets allow you to offset global
problems? With the Japan market slow and stagnant what other countries in
the region offer you the greatest opportunities and how can you succeed in
them. This report tells you.
Asian Developing Markets for Pharmaceuticals, 2006-2011 delivers to you
unique prospects for the largest developing pharmaceutical market - Asia.
This report predicts that all the leading developing markets will exhibit
strong growth from 2006-2011. Rapid economic growth and large, under-served
populations will drive that expansion in pharmaceutical revenues. There will
be significant growth in sales of both branded and generic drugs through
increasing demand from both public and private healthcare sectors. |
 |
"Outsourcing defines future of Euro Bioinformatics market"
"Jump on bioinformatics bandwagon"
These are just two newspaper headlines that appeared today. Managing your
data is critical to your organisation. You already know that. But is your
company doing it as effectively as it should? Find out by reading this brand
new report.
This report delivers answers on how you can benefit from the commercial
prospects of bioinformatics, now. The ultimate goal of bioinformatics is to
uncover the wealth of biological information hidden in the mass of data, to
obtain a clearer insight into the fundamental biology of organisms. Is your
Bioinformatic strategy working to the maximum level. These recent
developments have a profound relevance to pharmaceutical development. |
 |
More money is spent advertising alcohol than any other product. For
some, it like gambling and cigerettes are pleasant distractions, yet for
others they are the generators of unbearable cravings and the cause of
considerable distress. For them their addition is a disease. According to a
new report by visiongain - Anti-addiction Therapies, 2006-2011 - society is
crying out for solutions. Which pharmaceutical companies are now aiming to
be that cure? This report will tell you. |
 |
The number of people suffering from some sort of allergy is on the rise
and the demand for reliable treatments for allergic rhinitis and other
allergic conditions is on the rise worldwide. The market is a mature one
with a number of high profile patent losses in the near future and a strong
OTC segment. Will there be a replacement for Zyrtec or Allegra in the near
Future? What role will the new improved vaccines play in the next five
years? Read visiongain’s new report to find out. |
 |
In stark contrast to the rest of the pharmaceutical industry, the world
market for biotech drugs is thriving. In 2005, biotech revenues reached
$60bn and visiongain predicts that this will continue - YOU MUST BE PART OF
THIS SUCCESS NOW. Having grown 16.5 per cent from 2004's revenues,
double-digit growth of the market will continue to the end of the decade.
You need to be aware of how you can succeed in this area. 1 report will tell
you all you need to know.
- Over 250+ pages
- Over 150 tables and figures
- Global revenues & growth rates for the leading biotech drugs
- Company profiles of the leading biotech firms
- A comprehensive analysis of the global market, 2005-2011
- Revenue forecasts for the leading biotech drugs
- Revenues into therapeutic area
- Pipeline treatments
- A geographic breakdown of the market
- A Focus on biogenerics |
 |
The purpose of this visiongain report is to examine the prospects for
the growth of pharmaceutical revenues in the developing economies of Asia,
Latin America and Eastern/Central Europe at both regional and national
level. The growth of pharmaceutical markets in the developing nations has
the potential to offset serious problems currently experienced by the global
industry. The principal challenge is slow growth in North America, Western
Europe and Japan. |
 |
The asthma treatment market is a $15 billion market, driven by an
increasing prevalence and yet without a treatment to cure this debilitating
disease. All current drugs treat the symptoms but not the underlying cause.
It is currently dominated by GSK with its $5.5 billion blockbuster,
Advair/Seretide. However, this combination treatment is about to have its
first real competition with Symbicort approved for the US market in July
2006. Combination drugs appear likely to dominate the mid-term forecast
period as assessed by visiongain. |
 |
The Contract Pharma market in 2005 was worth an estimated $57bn.
Attitudes within the pharmaceutical industry are slowly changing and the use
of strategic outsourcing is becoming an accepted practice. Specialised
technologies and a global presence are becoming more important for a greater
number of pharmaceutical companies. Even big pharma is increasingly using
outsourcing to spread the risk of development and lower fixed costs. |
 |
The purpose of this visiongain report is to examine the commercial
prospects of online technologies in the pharmaceutical sector. In
particular, this report examines the fast-growing fields of pharmaceutical
eMarketing, eDetailing, ePrescribing and online drug sales. Online
technological solutions have great potential to benefit - even revolutionise
– the marketing efforts of drug companies. Visiongain predicts that all
aspects of pharmaceutical eMarketing will exhibit steady growth from
2006-2011. Key technological solutions - such as Internet-enabled DTC
promotion, eDetailing and ePrescribing - will drive that expansion. Sales of
prescription drugs via the Internet will also be significant. |
 |
At present ADRs are the sixth largest cause of death in the US. Drug
safety is a huge issue facing the industry today and the risk is high with
the possible loss of a key revenue producing drug coupled with potentially
damaging litigation. The financial risk facing Merck on the withdrawal of
Vioxx was considerably beyond the loss of its $2.5 bn yearly revenues. |
 |
The purpose of this visiongain report is to examine the commercial
prospects of nanotechnology in medicine – the fast-developing and
increasingly lucrative field of nanomedicine. Nanotechnology has great
potential to benefit - even revolutionise - the pharmaceutical, medical
devices, diagnostics and imaging sectors. Visiongain predicts that
nanomedicine will exhibit strong growth in all sectors from 2006-2011,
leading to multi-billion dollar revenues. Key technology platforms such as
nanocrystals, nanotubes, dendrimers, fullerenes, quantum dots and molecular
scaffolding will drive that market expansion. |
 |
The world biogenerics market is about to develop on a very large scale.
The approval of generic growth hormones in the US and Europe has finally
occurred and this has created a new source of revenue for generic companies.
After years of indecision and false starts, it appears that generic biotech
drugs are going to become available on the large, lucrative markets of the
US and Europe. However, despite the introduction of Biosimilar guidelines by
the EU and a heightening of the debate within the FDA, key questions for the
pharmaceutical industry still remain concerning this new type of generic
drug. The main issue is the degree to which the new biosimilar but not
bioequivalent generic drugs will have to be tested prior to market launch.
The delay in firm guidance and legislation is concerned almost entirely with
this issue. |
 |
The Indian pharmaceutical market is the 15th largest individual market
by sales, but the 4th by volume of product. With domestic drug sales of
almost $5 billion, Indian companies have also developed a considerable
service industry for the global pharmaceutical market. However the Indian
pharmaceutical market looks set for considerable change. |
 |
The global pharmaceutical market with sales of approximately $550
billion is about to enter a pivotal period in its history. The industry has
been used to double digit growth rates but growth has now dropped to below
10% for the first time. In addition to this whole swathes of lucrative high
revenue earning drugs are going to lose patent. Ordinarily, the industry
would have been able to cope with this after all patent loss is a normal
part of the industrial process. But this time the industry faces serious
problems, pipelines are notoriously thin. The industry is going to have huge
difficulties in replacing those drugs going off patent and the high levels
of revenue that they earn. The industry is going to have incorporate the new
culture of Product Lifecycle Management (PLM) if it is to salvage some of
those lost revenues. |
 |
In sharp contrast to the branded pharmaceutical market, which has
stalled in recent year, the generics market is enjoying a period of
unprecedented success. In 2005 the world generics market was worth $45bn, a
growth of 14% on the previous year. Visiongain expects this level of growth
to continue over the forecast period of this report. |
 |
Diabetes effects approximately 170 million people worldwide and is
increasing, with the WHO predicting 300 million diabetics by 2025. The US
alone has 20.8 million people suffering with diabetes. This equates to
approximately 6% of the population. It was the 6th most common cause of
death as recorded on US death certificates. |
 |
The purpose of this visiongain report is to examine the prospects of the
world gastrointestinal market. The gastrointestinal (GI) disorders market is
one of the largest and most important in the pharmaceutical industry,
generating revenues of over $16 billion in 2004. |
 |
The Japanese pharmaceutical market is the second largest individual
market and with sales of $60 billion constitutes approximately 11% of the
world market. However, it is a market that frustrates the major
pharmaceutical companies as it is growing at a significantly lower rate of
growth than the average of the world pharmaceutical markets. |
 |
In 2004 total world revenues for branded antidepressant drugs was worth
over $13bn, but with only ten drugs on the market. However, nine out of
these ten drugs faces a loss of patent in the period 2006-2010.
Dr Tom Newton, pharmaceutical analyst with visiongain and author of The
World Market for Antidepressants, 2006, predicts that the world market will
crash producing revenues in 2010 of only $7bn. This is a loss of almost 50%
of total revenues. |
 |
Generic companies and the drugs they produce are now an important part
of the major pharmaceutical markets. The growth rate in the industry is
increasing, nine of the top ten fastest growing pharmaceutical companies are
generic and the demand for cheaper drugs is increasing. |
 |
The world hypertension market generated over $25 billion in 2004, with
steady growth from the previous year. In this report, visiongain forecasts
that revenues in the world hypertension market will grow to nearly $30
billion per year by 2010. |
| |
|
